ELVN Stock Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Enliven Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.65 |
| 52 Week High | US$26.00 |
| 52 Week Low | US$9.80 |
| Beta | 0 |
| 1 Month Change | 21.77% |
| 3 Month Change | 46.98% |
| 1 Year Change | 15.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELVN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 31.8% | 1.1% | 0.7% |
| 1Y | 15.3% | 9.5% | 23.9% |
Return vs Industry: ELVN exceeded the US Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: ELVN underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| ELVN volatility | |
|---|---|
| ELVN Average Weekly Movement | 17.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ELVN's share price has been volatile over the past 3 months.
Volatility Over Time: ELVN's weekly volatility has increased from 12% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 46 | Sam Kintz | www.enliventherapeutics.com |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc. Fundamentals Summary
| ELVN fundamental statistics | |
|---|---|
| Market cap | US$1.06b |
| Earnings (TTM) | -US$71.58m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.8x
P/E RatioIs ELVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELVN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$71.58m |
| Earnings | -US$71.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ELVN perform over the long term?
See historical performance and comparison